Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, ÀûÀÀÁõº°, Åõ¿© °æ·Îº°, ȯÀÚ ¼Ó¼ºº°, À¯Åë ä³Îº°, Áö¿ªº°
Bipolar Disorder Mood Stabilizers Market, By Drug Type, By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Geography
»óǰÄÚµå
:
1747313
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀº 2025³â¿¡´Â 22¾ï 2,000¸¸ ´Þ·¯, 2032³â±îÁö´Â 26¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 2.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º¸°í¼ ¹üÀ§
º¸°í¼ »ó¼¼
±âÁØ ¿¬µµ
2024³â
2025³â ½ÃÀå ±Ô¸ð
22¾ï 2,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ
2020-2024³â
¿¹Ãø ±â°£
2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR
2.50%
2032³â ±Ý¾× ¿¹Ãø
26¾ï 4,000¸¸ ´Þ·¯
Á¶¿ïÁõÀ¸·Îµµ ¾Ë·ÁÁø ¾ç±Ø¼º Àå¾Ö´Â ±âºÐ, ¿¡³ÊÁö, Ȱµ¿ ¼öÁØ, ÀÏ»ó ¾÷¹« ¼öÇà ´É·Â¿¡ ºñÁ¤»óÀûÀÎ º¯È¸¦ ÀÏÀ¸Å°´Â ³ú ÁúȯÀÔ´Ï´Ù. Ç׿ì¿ïÁ¦´Â ¾ç±Ø¼º Àå¾Ö·Î ÀÎÇÑ ±Ø´ÜÀûÀÎ ±âºÐ º¯È¸¦ ¿¹¹æÇϰųª Ä¡·áÇϱâ À§ÇØ »ç¿ëµÇ´Â ¾à¹°ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾ç±Ø¼º Àå¾ÖÀÇ À¯º´·üÀÌ Áõ°¡Çϰí È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀº Áö³ ¸î ³â µ¿¾È Å« °ßÀÎÂ÷ ¿ªÇÒÀ» ÇØ¿Ô½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ Á¦¾à»çµéÀÇ R&D ÅõÀÚ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ
¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀº ÁÖ·Î À¯ÀüÀû ¿äÀΰú ¿Ü»ó¼º »ýȰ »ç°Ç ¹× ¾à¹° ³²¿ë°ú °°Àº ȯ°æÀû ¿äÀÎÀ¸·Î ÀÎÇÑ ¾ç±Ø¼º Àå¾ÖÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, 2024³â 7¿ù¿¡ ¹ßÇ¥µÈ WHO Åë°è¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î 4,500¸¸ ¸í ÀÌ»óÀÌ ¾ç±Ø¼º Àå¾Ö¸¦ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. À» ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ç¿ë °¡´ÉÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ ¸¹Àº ȯÀÚµéÀÌ ÀÇ·á Áö¿øÀ» ¿äûÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú ´õ È¿°úÀûÀÌ°í ³»¾à¼ºÀÌ °³¼±µÈ »õ·Î¿î ¾à¹° Á¦Á¦ÀÇ µµÀÔÀº ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Àú°³¹ß±¹¿¡¼´Â Á¤½ÅÀå¾ÖÀÇ Áø´Ü ¹× Ä¡·áÀ²ÀÌ ³·±â ¶§¹®¿¡ ½ÃÀå ÀáÀç·ÂÀº ¾ÆÁ÷ ¹Ì°³Ã´ »óÅÂÀÔ´Ï´Ù. ¶ÇÇÑ, ºê·£µå ÀǾàǰÀÇ ³ôÀº ºñ¿ëµµ °¡°Ý¿¡ ¹Î°¨ÇÑ ½ÃÀå¿¡¼ÀÇ Ã¤ÅÃÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, ƯÈ÷ Ä¡·á ÀúÇ×¼º ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ Ã·´Ü ¾à¹°¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̱⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È »õ·Î¿î ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
¼¼°èÀÇ ¾ç±Ø¼º Àå¾Ö ±âºÐ¾ÈÁ¤Á¦(Á¶¿ïÁõ Ä¡·áÁ¦) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ
¿µÇ⠺м®
ÁÖ¿ä ¹ßÀü
±ÔÁ¦ ½Ã³ª¸®¿À
Á¦Ç° ¹ß¸Å ¹× ½ÂÀÎ
PEST ºÐ¼®
PORTER ºÐ¼®
ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À
¾÷°è µ¿Çâ
Á¦4Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, ¾àÁ¦ À¯Çüº°, 2020³â-2032³â
Lithium
Lithium Carbonate
Lithium Citrate
Anticonvulsants
Valproic Acid/Valproate/Divalproex Sodium
Lamotrigine
Carbamazepine
Oxcarbazepine
Topiramate
Atypical Antipsychotics
Aripiprazole
Olanzapine
Quetiapine
Risperidone
Lurasidone
Ziprasidone
Asenapine
Calcium Channel Blockers
±âŸ(º´¿ë¿ä¹ý µî)
Á¦5Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, ÀûÀÀÁõº°, 2020³â-2032³â
¾ç±Ø¼º IÇü Àå¾Ö
¾ç±Ø¼º II Àå¾Ö
±âºÐ ¼øÈ¯¼º Àå¾Ö
È¥ÇÕ¼º Á¶¿ïÁõ
±Þ¼Ó ¼øÈ¯Çü Á¶¿ïÁõ
±âŸ
Á¦6Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2020³â-2032³â
°æ±¸
ºñ°æ±¸/ÁÖ»çÁ¦
°æÇÇ
±âŸ
Á¦7Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, ȯÀÚ ¼Ó¼ºº°, 2020³â-2032³â
¿¬·ÉÃþ
¾î¸°ÀÌ ¹× û¼Ò³â
¼ºÀÎ
°í·ÉÀÚ
¼ºº°
³²¼º
¿©¼º
Á¦8Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â
º´¿ø ¾à±¹
¼Ò¸Å ¾à±¹
¿Â¶óÀÎ ¾à±¹
Á¦9Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, Áö¿ªº°, 2020³â-2032³â
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
¸ß½ÃÄÚ
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
µ¶ÀÏ
¿µ±¹
½ºÆäÀÎ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
Áß±¹
Àεµ
ÀϺ»
È£ÁÖ
Çѱ¹
ASEAN
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
秵GCC ±¹°¡
À̽º¶ó¿¤
±âŸ Áßµ¿
¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«
ºÏ¾ÆÇÁ¸®Ä«
Áß¾Ó¾ÆÇÁ¸®Ä«
Á¦10Àå °æÀï ±¸µµ
Eli Lilly and Company
AstraZeneca PLC
Johnson & Johnson
Pfizer Inc.
AbbVie Inc.
Bristol-Myers Squibb
GlaxoSmithKline
Sanofi S.A.
Merck & Co.
Teva Pharmaceutical Industries
Novartis AG
Otsuka Pharmaceutical
Lundbeck A/S
Takeda Pharmaceutical Company
Alkermes plc
Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È
Wheel of Fortune
¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
Coherent Opportunity Map
Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
Âü°í ¹®Çå
Á¶»ç ¹æ¹ý
ÃâÆÇ»ç¿¡ ´ëÇØ
LSH
¿µ¹® ¸ñÂ÷
The Global Bipolar Disorder Mood Stabilizers Market is estimated to be valued at USD 2.22 Bn in 2025 and is expected to reach USD 2.64 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 2.5% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 2.22 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
2.50%
2032 Value Projection:
USD 2.64 Bn
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Mood stabilizers are a class of drugs used to prevent or treat the extreme mood swings associated with bipolar disorder. The global bipolar disorder mood stabilizers market has been gaining significant traction over the past few years, owing to the rising prevalence of bipolar disorder worldwide and growing awareness regarding its effective treatment options. Increasing R&D investments by pharmaceutical companies to develop novel treatment alternatives are also propelling the market growth.
Market Dynamics
The global bipolar disorder mood stabilizers market is primarily driven by the growing prevalence of bipolar disorder caused by genetic and environmental factors such as traumatic life events and substance abuse. As per WHO statistics released in July 2024, over 45 million people worldwide suffer from bipolar disorder. Furthermore, rising awareness about available treatment options and increased healthcare spending are encouraging more patients to seek medical help. Meanwhile, continuous innovations and introduction of new drug formulations with higher efficacy and improved tolerability are helping expand the market reach. However, the market potential is still untapped in underdeveloped economies due to low diagnosis and treatment rates of mental disorders. High costs of branded drugs also limit their adoption in price-sensitive markets. Nonetheless, ongoing clinical trials for advanced drugs, especially for treatment-resistant patients, are expected to introduce new opportunities during the forecast period.
Key Features of the Study
This report provides in-depth analysis of the global bipolar disorder mood stabilizers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bipolar disorder mood stabilizers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, GlaxoSmithKline, Sanofi S.A., Merck & Co., Teva Pharmaceutical Industries, Novartis AG, Otsuka Pharmaceutical, H. Lundbeck A/S, Takeda Pharmaceutical Company, and Alkermes plc
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bipolar disorder mood stabilizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder mood stabilizers market
Market Segmentation
Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
Lithium
Lithium Carbonate
Lithium Citrate
Anticonvulsants
Valproic Acid/Valproate/Divalproex Sodium
Lamotrigine
Carbamazepine
Oxcarbazepine
Topiramate
Atypical Antipsychotics
Aripiprazole
Olanzapine
Quetiapine
Risperidone
Lurasidone
Ziprasidone
Asenapine
Calcium Channel Blockers
Others (Combination Therapies, etc.)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
Bipolar I Disorder
Bipolar II Disorder
Cyclothymic Disorder
Mixed Features Bipolar Disorder
Rapid Cycling Bipolar Disorder
Others
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
Oral
Parenteral/Injectable
Transdermal
Others
Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
Age Groups
Children and adolescents
Adults
Elderly
Gender
Male
Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Key Players Insights
Eli Lilly and Company
AstraZeneca PLC
Johnson & Johnson
Pfizer Inc.
AbbVie Inc.
Bristol-Myers Squibb
GlaxoSmithKline
Sanofi S.A.
Merck & Co.
Teva Pharmaceutical Industries
Novartis AG
Otsuka Pharmaceutical
Lundbeck A/S
Takeda Pharmaceutical Company
Alkermes plc
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Bipolar Disorder Mood Stabilizers Market, By Drug Type
Global Bipolar Disorder Mood Stabilizers Market, By Indication
Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration
Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics
Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel
Global Bipolar Disorder Mood Stabilizers Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends
4. Global Bipolar Disorder Mood Stabilizers Market, By Drug Type, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Lithium
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lithium Carbonate
Lithium Citrate
Anticonvulsants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Valproic Acid/Valproate/Divalproex Sodium
Lamotrigine
Carbamazepine
Oxcarbazepine
Topiramate
Atypical Antipsychotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Aripiprazole
Olanzapine
Quetiapine
Risperidone
Lurasidone
Ziprasidone
Asenapine
Calcium Channel Blockers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Combination Therapies, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Bipolar Disorder Mood Stabilizers Market, By Indication, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Bipolar I Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar II Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cyclothymic Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Mixed Features Bipolar Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rapid Cycling Bipolar Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral/Injectable
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Transdermal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Age Groups
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Children and adolescents
Adults
Elderly
Gender
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Male
Female
8. Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Bipolar Disorder Mood Stabilizers Market, By Region, 2020 - 2032, Value (USD Bn)
Introduction
Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Latin America
Introduction
Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
South Africa
North Africa
Central Africa
10. Competitive Landscape
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Teva Pharmaceutical Industries
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Otsuka Pharmaceutical
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Lundbeck A/S
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Takeda Pharmaceutical Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Alkermes plc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
11. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
12. References and Research Methodology
References
Research Methodology
About us
°ü·ÃÀÚ·á